Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free.
A mass vaccination campaign that targeted frontline workers to receive the vaccine began on Dec. 8. Within 24 hours of launching the campaign, MHRA acknowledged two reports of anaphylaxis and one report of a possible allergic reaction.
Imperial College London’s Paul Turner, an expert in allergy and immunology who has been advising the MHRA on its revised guidance, told Reuters: “The ingredients like PEG which we think might be responsible for the reactions are not related to things which can cause food allergy. Likewise, people with a known allergy to just one medicine should not be at risk.”
It was also reported that PEG, which helps to stabilize the shot, is not in other types of vaccines.
The statements by Turner that “PEG is not in other types of vaccines” and that people with allergies to “just one medicine should not be at risk” are a failed attempt to provide false assurances and are patently untrue.
Moderna, Pfizer/BioNTech and Arcturus Therapeutics COVID vaccines all utilize a never-before-approved messenger RNA (mRNA) technology, an experimental approach designed to turn the body’s cells into viral protein-making factories. This technology involves the use of lipid nanoparticles (LNPs) that encapsulate the mRNA to protect them from degradation and promote cellular uptake.
The LNP formulations in the three COVID-19 mRNA vaccines are “PEGylated,” meaning that the vaccine nanoparticles are coated with a synthetic, non-degradable and increasingly controversial PEG.
COVID mRNA vaccines are not the only vehicle for PEG involvement in COVID-19 vaccine production. Researchers at Germany’s Max Planck Institute report developing a process for COVID-19 vaccine production to purify virus particles at “high yield.” The process involves adding PEG to a virus-containing liquid and passing the liquid through membranes.
On Sept. 25, Robert F. Kennedy, Jr., chairman and chief legal counsel for Children’s Health Defense (CHD), notified the Steven Hahn, director of the U.S. Food and Drug Administration (FDA), Dr. Peter Marks director of FDA’s Center for Biologics Evaluation and Research and Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases, of the serious and possibly life-threatening anaphylactic potential of PEG.
CHD received the following response from the FDA, on Dec. 2, but has not yet received a response from Fauci.
In earlier communications with Moderna scientists regarding the controversial use of PEG in the company’s COVID-19 vaccine due to the potential for life-threatening anaphylaxis and need for pre-screening for PEG antibodies prior to vaccine administration, they insisted that the existence of PEG antibodies was purely hypothetical and underserving of concern:
“Pre-screening populations based on hypothesized biomarkers, such as anti-PEG antibodies, is not a strategy currently employed in our clinical trials.”
Given the recent evidence of PEG anaphylaxis in Pfizer mRNA vaccine recipients, I wonder if FDA and vaccine manufacturers will now reconsider their position.
An extensive review of PEG therapeutics, published in 2013, documented adverse effects of PEGylation and questioned the wisdom behind the continued use of PEG in drug development. The authors concluded that “the accumulating evidence documenting the detrimental effects of PEG on drug delivery make it imperative that scientists in this field break their dependence on PEGylation.”
The statement by Turner that “people with a known allergy to just one medicine should not be at risk,” is also not true.
A 2018 study, “Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized” reports there are more than 1,000 products, including prescription drugs, that contain PEG. (See chart below for detailed descriptions of PEG containing drugs.)
The decision to allow people with other medication allergies to receive vaccines that utilize PEG in the manufacturing or delivery of the vaccine is a very risky proposition — especially given that Pfizer has said people with a history of severe adverse allergic reactions to vaccines or the candidate’s ingredients were excluded from their late stage trials.
We have no idea what the incidence of allergy or anaphylactic reactions will be once Pfizer begins global distribution of the vaccine, without such exclusions.
A 2016 study reported detectable and sometimes high levels of anti-PEG antibodies in approximately 72% of contemporary human samples and about 56% of historical specimens from the 1970s through the 1990s. The population’s increased exposure to PEG-containing products since the 1990’s makes it natural to assume that anti-PEG antibodies will continue to be widespread.
As approval of PEGylated mRNA vaccines for COVID-19 occurs, the uptick in exposure to injected PEG products will be unprecedented and potentially disastrous.
While four out of five doctors regularly prescribe PEGylated drugs, only one out of five are aware of the potential for anti-PEG antibody responses. And only a third even know that PEG is in the drugs that they are prescribing.
A Vanderbilt University researcher agrees that there is a widespread lack of recognition that PEG hypersensitivity is possible, much less that it manifests on a regular basis. While it has been recommended to screen patients for anti-PEG antibody levels “prior to administration of therapeutics containing PEG” such testing is currently only available in research settings.
In a declaration effective Feb. 4, the Secretary of Health and Human Services invoked the Public Readiness and Emergency Preparedness Act (PREP Act) and declared Coronavirus Disease 2019 (COVID-19) to be a public health emergency warranting liability protections for covered countermeasures, including vaccines.
The fact that the FDA has abdicated its responsibility for assuring the safety of COVID vaccines to vaccine manufacturers means we are on our own to study the science, and weigh the benefits and risks of all drugs and vaccines.
CHD will continue to monitor this important safety issue in an effort to keep you well informed on the science and public policies surrounding COVID-19 vaccine development.
Descriptions of PEG containing drugs: